Plasma lipoprotein(a) levels in subjects attending a metabolic ward: Discrimination between individuals with and without a history of ischemic stroke

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 16, Issue 1, 1996, Pages 120-128

  Margaglione, Maurizio ^b   DiMinno, Giovanni ^a,b,c   Grandone, Elvira ^a,b   Celentano, Egidio ^a   Vecchione, Gennaro ^b   Cappucci, Giuseppe ^b   Grilli, Massimo ^b   Mancini, Francesco Paolo ^a   Postiglione, Alfredo ^a   Panico, Salvatore ^a   Mancini, Mario ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^c Clinica Medica   (Italy)

Author keywords

fibrinolytic variables; genotype; ischemic stroke; lipoprotein(a)

Indexed keywords

LIPOPROTEIN A;

ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; DISEASE ASSOCIATION; DNA FLANKING REGION; DNA POLYMORPHISM; FEMALE; GENE ISOLATION; GENETIC VARIABILITY; HUMAN; HUMAN EXPERIMENT; LIPOPROTEIN BLOOD LEVEL; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; RISK FACTOR; STATISTICAL ANALYSIS;

EID: 9044247066     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.16.1.120     Document Type: Article

References (51)

1. Berg K. A new serum type system: the Lp-system. Acta Pathol Scand. 1963;59(suppl 166/167);369-382.
2. Seed M, Hoppichler F, Reaveley D, McCarthy S, Thompson GR, Boerwinkle E, Uteran G. Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotypc to coronary heart disease in patients with familial hypercholesterolemia. N Engl J Med. 1990; 322:1494-1499.
3. Wiklund O, Angelin B, Olofsson SO, Eriksson M, Fager G, Berglund L, Bondjers G. Apolipoprotein(a) and ischemic heart disease in familial hypercholestcrolemia. Lancet. 1990;335: 1360-1363.
4. Schaefer EJ, Lamon-Fava S, Jenner J, McNamara JR, Ordovas JM, Davis CE, Abolafia SM, Lippel K, Levy RI. Lipoprotein(a) levels and risk of coronary heart disease in men: the Lipid Research Clinics Coronary Primary Prevention Trial. JAMA. 1994;271: 999-1003.
5. Rhoads G, Dahlen G, Berg K, Morton NE, Dannenberg AL. Lp(a) lipoprotein as a risk factor for myocardial infarction. JAMA. 1986; 18:2540-2544.
6. Sandkamp M, Funke H, Shulte H, Kohler E, Assmann G. Lipoprotein(a) is an independent risk factor for myocardial infarction at young age. Clin Chem. 1990;36:20-23.
7. Armstrong VW, Cremer P, Eberle E, Manke A, Schulze F, Wieland H, Kreuzer H, Seidel D. The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Atherosclerosis. 1986;62:249-257.
8. Dahlen GH, Guyton JR, Arrar M, Farmer JA, Kautz JA, Gotto AM. Association of level of lipoprotein(a), plasma lipids and other lipoproteins with coronary artery disease documented by angiography. Circulation. 1986;74:758-765.
9. Hoff HF, Beck GJ, Skibinski CI, Jurgens G, O'Neil J, Kramer J, Lytle B. Serum Lp(a) level as a predictor of vein graft stenosis after coronary artery bypass surgery in patients. Circulation. 1988;76: 1238-1244.
10. Zenker G, Koltringer P, Noné G, Niederkorn K, Pfeiffer K, Jurgens J. Lipoprotcin(a) as a strong indicator for cerebrovascular disease. Stroke. 1986;17:942-945.
11. Murai A, Miyahara T, Fujimoto N, Matsuda M, Kameyama M. Lp(a) as a risk factor for coronary heart disease and cerebral infarction. Atherosclerosis. 1986;59:199-204.
12. Jauhiainen M, Koskinen P, Ehnholm C, Frick MH, Manttari M, Manninen V, Huttunen JK. Lipoprotein(a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. Atherosclerosis. 1991;89:59-67.
13. Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA. 1993; 270:2195-2199.
14. Marburger C, Hambrecht R, Niebauer J, Schoeppenthau M, Scheffler E, Hauer K, Schulter G, Schlierf G. Association between lipoprotein(a) and progression of coronary artery disease in middle-aged men. Am J Cardiol. 1994,73:742-746.
15. Ridker PM, Stampfer MJ, Hennekens CH. Plasma concentrations of lipoprotein(a) and the risk of future stroke. JAMA. 1995;278: 1269-1273.
16. Etingin OR, Hajjar DP, Hajjar KA, Harpel PC, Nachman RL. Lipoprotein(a) regulates plasminogen activator inhibitor-1 expression in endothelial cells: a potential mechanism in thrombogenesis. J Biol Chem. 1991;288:2459-2465.
17. Scanu AM, Fless GM. Lipoprotein (a) heterogeneity and biological relevance. J Clin Invest. 1990;85:1709-1715.
18. Margaglione M, Di Minno G, Grandone E, Vecchione A, Celentano E, Capucci A, Grilli M, Simone P, Panico S, Mancini M. Abnormally high circulating levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in subjects with a history of ischemic stroke. Arterioscler Thromb. 1994;14:1741-1745.
19. Cohen JC, Chiesa G, Hobbs HH. Sequence polymorphisms in the apolipoprotein(a) gene. Evidence for dissociation between apoprotein(a) size and plasma lipoprotcin(a) levels. J Clin Invest. 1993;91: 1630-1636.
20. Wade DP, Klarke JC, Lindahl GE, Liu AC, Zysow BR, Meer K, Schwartz K, Lawn RM. 5′ control regions of the apoprotein(a) gene and members of the related plasminogen gene family. Proc Natl Acad Sci U S A. 1993;90:1369-1373.
21. Margaglione M, Di Minno G, Grandone E, Vecchione G, Celentano E, Cappucci G, Giordano M, Grilli M, Simone P, Fusilli S, Panico S, Mancini M. Raised plasma fibrinogen concentrations in subjects attending a metabolic ward: relation to family history and vascular risk factors. Thromb Haemost. 1995,73:479-483.
22. Anderson CS, Jamrozik KD, Broadhurst RJ, Stewart-Wynne EG. Predicting survival for 1 year among different subtypes of stroke: results from the Perth Community Stroke Study. Stroke. 1994;25: 1935-1944.
23. Norusis MJ. SPSS/PC+ Base Manual. Version 2.0. Chicago, III: SPSS, Inc; 1988.
24. Sing CF, Davignon J. Role of apoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. Am J Hum Genet. 1985;37:268-285.
25. Nagayama M, Shinohara Y, Nagayama T. Lipoprotein(a) and ischemic cerebrovascular disease in young adults. Stroke. 1994;25: 74-78.
26. Shintani S, Kikuchi S, Hamaguchi H, Shiigai T. High serum lipoprotein(a) levels are an independent risk factor for cerebral infarction. Stroke. 1993;24:965-969.
27. Rosengren A, Wilhelmsen L, Eriksson E, Risberg D, Wedel H. Lipoprotein(a) and coronary heart disease: a prospective case-control study in a general population of middle aged men. BMJ. 1990;301:1248-1251.
28. Hearn JA, De Maio SJ, Roubin GS, Hammarstrom M, Sgoutas D. Predictive value of lipoprotein(a) and other serum lipoproteins in the angiographic diagnosis of coronary artery disease. Am J Cardiol. 1990;66:1176-1180.
29. Maeda S, Abe A, Seishima M, Makino K, Noma A, Kamade M. Transient changes of serum lipoprotein(a) as an acute-phase protein. Atherosclerosis. 1989;78:145-150.
30. Tohgi H, Takahashi H, Chiba K, Tamura K. Coagulation/fibrinolysis system in poststroke patients receiving antiplatelet medication. Stroke. 1993;24:940-943.
31. Bachmann F. Molecular aspects of plasminogen, plasminogen activators and plasmin. In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EG, eds. Haemostasis and Thrombosis. Edinburgh, Scotland: Churchill Livingstone; 1994:575-614.
32. Di Minno G, Cerbone AM, Mattioli PL, Turco S, Iovine C, Mancini M. Functionally thrombasthenic state in normal platelets following the administration of ticlopidine. J Clin Invest. 1985;75:328-338.
33. Ozturk S, Bruck D, Feinberg WM. Coagulation-fibrinolysis abnormalities in poststroke patients. Stroke. 1994;25;1702-1703. Letter.
34. Kimura S, Nishinaga M, Ozawa T, Shimada K. Thrombin generation as an acute effect of cigarette smoking. Am Heart J. 1994; 128;7-11.
35. Sacco RL, Ellenberg JH, Mohr JP, Tatemichi TK, Hier DB, Price TR, Wolf PA. Infarcts of undetermined cause: the NINCDS Stroke Data Bank. Ann Nenrol. 1989;25:382-390.
36. Jurgens G, Koltringer P. Cerebrovascular disease and Lp(a): its role in atherosclerotic plaque formation and vessel wall elasticity of the carotid arteries. Chem Phys Lipids. 1994;67/68:429-434.
37. Millikan C, Futrell N. The fallacy of the lacune hypothesis. Stroke. 1990;21:1251-1257.
38. Botet JP, Sentí M, Nogues X, Prat JR, Roquer J, D'Olhaberrigue L, Olive J. Lipoprotein and apoprotein profile in men with ischemic stroke: role of lipoprotein(a), triglyceride-rich lipoproteins, and apoprotein E polymorphism. Stroke. 1992;23:1556-1562.
39. Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. Apoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest. 1992;90: 52-60.
40. Hamsten A, Wiman B, De Faire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator inhibitor in young survivors of stroke or myocardial infarction. N Engl J Med. 1985;313:1557-1563.
41. Paramo JA, Colucci M, Collen D, van de Werf F. Plasminogen activator inhibitor in the blood of patients with coronary artery disease. BMJ. 1985;291:573-574.
42. Hamsten A, Blomback M, Wiman B, Svensson J, Szamosi A, De Faire U, Mettinger L. Haemostatic function in myocardial infarction. Br Heart J. 1986;55:58-66.
43. Aznar J, Estelles A, Tormo G, Sapena P, Blanch S, Espana F. Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease. Br Heart J. 1988;59:535-541.
44. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet. 1993;342:1076-1079.
45. Hamsten A, De Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987;2:3-9.
46. Auwerx J, Bouillon R, Collen D, Gebeors J. Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis. 1988;8:68-72.
47. Juhan-Vague I, Alessi MC, Joly P, Thiriou W, Vague P, Declerck PJ, Senadimigni A, Collen D. Plasma plasminogen activator inhibitor-1 in angina pectoris: influence of plasma insulin and acute-phase response. Arteriosclerosis. 1989;9:381-387.
48. ECAT Angina Pectoris Study Group. ECAT angina pectoris study: baseline associations of hemostatic factors with extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography. Eur Heart J. 1993;14:8-17.
49. Gray RP, Patterson DLH, Yudkin JS. Plasminogen activator inhibitor activity in diabetic and nondiabetic survivors of myocardial infarction. Arterioscler Thromb. 1993;13:415-420.
50. Jansonn JH, Olofsson BO, Nilsson TK. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary heart disease. Circulation. 1993;88: 2030-2034.
51. Ridker PM, Hennekens CH, Stampfer MJ, Manson J, Vaughan DE. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet. 1994;343:940-943.